Yarbrough Capital’s Sarepta Therapeutics SRPT Stock Holding History

Yarbrough Capital’s Portfolio SRPT Stock Details SRPT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q1	–	Sell	-2,790	Closed	-$339K	–	209
2024 Q4	$339K	Hold	2,790	–	–	0.01%	160
2024 Q3	$348K	Hold	2,790	–	–	0.01%	171
2024 Q2	$441K	Hold	2,790	–	–	0.02%	138
2024 Q1	$361K	Hold	2,790	–	–	0.02%	167
2023 Q4	$269K	Hold	2,790	–	–	0.01%	187
2023 Q3	$338K	Hold	2,790	–	–	0.02%	168
2023 Q2	$320K	Buy	+2,790	New	+$360K	0.02%	173
2022 Q1	–	Sell	-2,518	Closed	-$227K	–	227
2021 Q4	$227K	Buy	+2,518	New	+$215K	0.01%	212

Other funds holding SRPT

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Yarbrough Capital's SRPT Position: Q1 2025 in Review

Yarbrough Capital sold out of Sarepta Therapeutics (SRPT) in Q1 2025, closing a stake of 2,790 shares — an estimated $339K sold.

Yarbrough Capital first reported a position in SRPT in Q4 2021 and held it in 8 quarters. The position peaked at $441K in Q2 2024. 430 funds tracked by Wall St. Rank hold SRPT as of Q1 2025.

Yarbrough Capital reported no remaining Sarepta Therapeutics position as of Q1 2025 after selling out during the quarter.
Yarbrough Capital sold 2,790 Sarepta Therapeutics shares in Q1 2025, an estimated $339K.
Yarbrough Capital first reported a position in Sarepta Therapeutics in Q4 2021 and held it in 8 quarters.
Yarbrough Capital's Sarepta Therapeutics position peaked at $441K in Q2 2024.
430 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q1 2025.

Based on Yarbrough Capital's 13F filing for Q1 2025, filed 14 Apr 2025.